NASDAQ: CODX - Co-Diagnostics, Inc.

Rentabilität für sechs Monate: -40.65%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Co-Diagnostics, Inc.


Über das Unternehmen

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

weitere details
It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

IPO date 2017-07-12
ISIN US1897631057
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.codiagnostics.com
Цена ао 1.12
Preisänderung pro Tag: -3.74% (0.7584)
Preisänderung pro Woche: 0% (0.73)
Preisänderung pro Monat: -22.03% (0.9363)
Preisänderung über 3 Monate: -40.65% (1.23)
Preisänderung über sechs Monate: -40.65% (1.23)
Preisänderung pro Jahr: -45.11% (1.33)
Preisänderung über 3 Jahre: -91.51% (8.6)
Preisänderung über 5 Jahre: -21.05% (0.9246)
Preisänderung über 10 Jahre: 0% (0.73)
Preisänderung seit Jahresbeginn: -22.03% (0.9363)

Unterschätzung

Name Bedeutung Grad
P/S 34.04 1
P/BV 0.3924 10
P/E 0 0
EV/EBITDA -0.4614 0
Gesamt: 4.75

Effizienz

Name Bedeutung Grad
ROA, % -34.09 0
ROE, % -41.08 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0632 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 3068.39 10
Rentabilität Ebitda, % 591.26 10
Rentabilität EPS, % 232.41 10
Gesamt: 10

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
iShares Micro-Cap ETF 0.00999 17.09 1.54048



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Dwight H. Egan Chairman & CEO 415.75k 1953 (72 Jahr)
Mr. Brian L. Brown CPA CFO & Company Secretary 338.92k 1976 (49 Jahre)
Dr. Brent C. Satterfield Ph.D. Co-Founder & Member of Scientific Advisory Board 237.5k 1977 (48 Jahre)
Mr. Dan Bohrer CPA Vice President of Finance & Accounting N/A
Mr. Andrew Benson Head of Investor Relations N/A
Dr. Mayuranki Almaula Senior Vice President of Overseas Operations & Strategic Alliances N/A
Mr. Richard David Abbott President N/A 1972 (53 Jahr)
Mr. David Nielsen Chief Operating Officer N/A
Mr. Christopher Thurston Chief Technology Officer N/A
Mr. Cameron Gundry Head of Commercialization LATAM/EUR

Adresse: United States, Salt Lake City. UT, 2401 South Foothill Drive - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.codiagnostics.com